PAIN
Volume 142, Issue 3 , Pages 209-217 , April 2009

A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster

  • Robert H. Dworkin

      Affiliations

    • Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 585 275 3524; fax: +1 585 473 5007.
    • ,
  • Richard L. Barbano

      Affiliations

    • Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Stephen K. Tyring

      Affiliations

    • Department of Dermatology, University of Texas Health Science Center and the Center for Clinical Studies, Houston, TX, USA
    • ,
  • Robert F. Betts

      Affiliations

    • Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Michael P. McDermott

      Affiliations

    • Departments of Biostatistics and Computational Biology and Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Janet Pennella-Vaughan

      Affiliations

    • Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Gary J. Bennett

      Affiliations

    • Department of Anesthesiology, McGill University, Montreal, Canada
    • ,
  • Erhan Berber

      Affiliations

    • Novartis Pharmaceuticals, East Hanover, NJ, USA
    • ,
  • John W. Gnann

      Affiliations

    • Departments of Medicine, Pediatrics, and Microbiology, University of Alabama at Birmingham and Birmingham Veterans Administration Medicine Center, Birmingham, AL, USA
    • ,
  • Carrie Irvine

      Affiliations

    • Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Cornelia Kamp

      Affiliations

    • Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Karl Kieburtz

      Affiliations

    • Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
    • ,
  • Mitchell B. Max

      Affiliations

    • Department of Anesthesiology, University of Pittsburgh, Pittsburgh, PA, USA
    • ,
  • Kenneth E. Schmader

      Affiliations

    • Department of Medicine-Geriatrics, Duke University, and GRECC, Durham VA Medical Center, Durham, NC, USA

Received 3 September 2008 ,Revised 10 November 2008 ,Accepted 15 December 2008.

References 

  1. Anderson K, Syrjala KL, Cleeland CS. How to assess cancer pain. In:  Turk DC,  Melzack R editor. Handbook of pain assessment. 2nd ed.. New York: Guilford Press; 2001;p. 579–600
  2. Bajwa ZH, Ho CC. Herpetic neuralgia: use of combination therapy for pain relief in acute and chronic herpes zoster. Geriatrics. 2001;56:18–24
  3. Bennett GJ. Hypotheses on the pathogenesis of herpes zoster-associated pain. Ann Neurol. 1994;35:S38–S41
  4. Berry JD, Petersen KL. A single dose of gabapentin reduces acute pain and allodynia inpatients with herpes zoster. Neurology. 2005;65:444–447
  5. Brentjens MH, Torres G, He J, Lee PC, Tyring SK. Reduction of postherpetic neuralgia in herpes zoster: a study of the effects of gabapentin with valacyclovir during acute zoster outbreaks. Annual meeting of the American Academy of Dermatology, San Francisco, March 2003.
  6. Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol. 2003;70:S31–S37
  7. Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect. 2001;127:305–314
  8. Cepeda MS, Africano JM, Polo R, Alcala R, Carr DB. What decline in pain intensity is meaningful to patients with acute pain?. Pain. 2003;105:151–157
  9. Coplan PM, Schmader K, Nikas A, Chan ISF, Choo P, Levin MJ, et al. Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the Brief Pain Inventory. J Pain. 2004;5:344–356
  10. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959–965
  11. Dworkin RH, Corbin AE, Young JP, Sharma U, LaMoreaux L, Bockbrader H, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003;60:1274–1283
  12. Dworkin RH, Johnson RW, Breuer J, Gnann JW, Levin MJ, Backonja M, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44:S1–26
  13. Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Jensen TS, Kalso EA, et al. Pharmacologic management of neuropathic pain: evidence-based clinical recommendations. Pain. 2007;132:237–251
  14. Dworkin RH, Schmader KE. The epidemiology and natural history of herpes zoster and postherpetic neuralgia. In:  Watson CPN,  Gershon AA editor. Herpes zoster and postherpetic neuralgia. 2nd ed.. New York: Elsevier press; 2001;p. 39–64
  15. Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19
  16. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9:105–121
  17. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94:149–158
  18. Filadora VA, Sist TC, Lema MJ. Acute herpetic neuralgia and postherpetic neuralgia in the head and neck: response to gabapentin in five cases. Reg Anesth Pain Med. 1999;24:170–174
  19. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005;118:289–305
  20. Garnett GP, Ferguson NM. Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev Med Virol. 1996;6:151–161
  21. Garry EM, Delaney A, Anderson HA, Sirinathsinghji EC, Clapp RH, Martin WJ, et al. Varicella zoster virus induces neuropathic changes in rat dorsal root ganglia and behavioral reflex sensitisation that is attenuated by gabapentin or sodium channel blocking drugs. Pain. 2005;118:97–111
  22. Gnann JW, Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF, et al. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Antimicrob Agents Chemother. 1998;42:1139–1145
  23. Gnann JW, Whitley RJ. Herpes zoster. N Engl J Med. 2002;347:340–346
  24. Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, et al. Further characterization of a rat model of varicella zoster virus-associated pain: relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs. Neuroscience. 2007;144:1495–1508
  25. Hempenstall K, Nurmikko TJ, Johnson RW, A’Hern RP, Rice ASC. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med. 2005;2:628–644
  26. Higa K, Mori M, Hirata K, Hori K, Manabe H, Dan K. Severity of skin lesions of herpes zoster at the worst phase rather than age and involved region most influences the duration of acute herpetic pain. Pain. 1997;69:245–253
  27. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9–20
  28. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract. 1975;25:571–575
  29. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20:748–753
  30. Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4:407–414
  31. Jung BF, Johnson RW, Griffin DRJ, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62:1545–1551
  32. Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health-related quality of life. Clin Infect Dis. 2004;39:342–348
  33. Kuraishi Y, Takasaki I, Nojima H, Shiraki K, Takahata H. Effects of the suppression of acute pain by gabapentin and amitriptyline on the incidence of delayed postherpetic pain in mice. Life Sci. 2004;74:2619–2626
  34. Kurtzke JF. Neuroepidemiology. Ann Neurol. 1984;16:265–277
  35. Melzack R. The short-form McGill pain questionnaire. Pain. 1987;30:191–197
  36. Oaklander AL. Mechanisms of pain and itch caused herpes zoster (shingles). J Pain. 2008;9:S10–S18
  37. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352:2271–2284
  38. Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO. Population-based study of herpes zoster and its sequelae. Medicine. 1982;61:310–316
  39. Rice ASC, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain. 2001;94:215–224
  40. Rowbotham MC, Baron R, Petersen KL, Fields HL. Spectrum of pain mechanisms contributing to PHN. In:  Watson CPN,  Gershon AA editor. Herpes zoster and postherpetic neuralgia. 2nd ed.. New York: Elsevier; 2001;p. 183–195
  41. Rowbotham MC, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837–1842
  42. Russell ML, Schopflocher P, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect. 2007;135:908–913
  43. Schmader KE, Sloane R, Pieper C, Coplan PM, Nikas A, Saddier P, et al. The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain. 2007;23:490–496
  44. Schuette MC, Hethcote HW. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol. 1999;61:1031–1064
  45. Whitley RJ, Weiss H, Gnann JW, Tyring S, Mertz GJ, Pappas PG, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med. 1996;125:376–383
  46. Whitley RJ, Weiss HL, Soong SJ, Gnann JW. Herpes zoster: risk categories for persistent pain. J Infect Dis. 1999;179:9–15
  47. Woolf CJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci. 2004;74:2605–2610
  48. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health. 2005;5:68

PII: S0304-3959(08)00761-6

doi: 10.1016/j.pain.2008.12.022

PAIN
Volume 142, Issue 3 , Pages 209-217 , April 2009

Article Tools

* Image Usage & Resolution